Institute for Stem Cell Biology and Regenerative Medicine
Showing 51-100 of 133 Results
-
Daniel Dan Liu
MD Student, expected graduation Spring 2024
Ph.D. Student in Stem Cell Biology and Regenerative Medicine, admitted Autumn 2020
MSTP Student
Ph.D. Minor, Computer ScienceBioDaniel received his bachelor's in molecular biology from Princeton University in 2018. His undergraduate research, conducted under the mentorship of Dr. Yibin Kang, centered around cancer metastasis and cancer stem cell biology. He is currently an MD-PhD candidate in the lab of Dr. Irving Weissman, where he researches human neural stem cells and primary brain malignancies.
-
Kyle Loh
Assistant Professor of Developmental Biology (Stem Cell)
BioHow the richly varied cell-types in the human body arise from one embryonic cell is a biological marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different human cell-types. This roadmap allowed us to generate enriched populations of human liver, bone, heart and blood vessel precursors in a Petri dish from embryonic stem cells. Each of these tissue precursors could regenerate their cognate tissue upon injection into respective mouse models, with relevance to regenerative medicine. In addition to our interests in developmental and stem cell biology, we also interested in discovering the entry receptors and target cells of deadly biosafety level 4 viruses, together with our collaborators.
Kyle attended the County College of Morris and Rutgers University, and received his Ph.D. from Stanford University (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute for Talent Development. He then continued as a Siebel Investigator, and later, as an Assistant Professor and The Anthony DiGenova Endowed Faculty Scholar at Stanford, where he is jointly appointed in the Department of Developmental Biology and Institute for Stem Cell Biology & Regenerative Medicine. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar, and his research has been recognized by the NIH Director's Early Independence Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship. -
Dr. Michael T. Longaker
Deane P. and Louise Mitchell Professor in the School of Medicine and Professor, by courtesy, of Materials Science and Engineering
Current Research and Scholarly InterestsWe have six main areas of current interest: 1) Cranial Suture Developmental Biology, 2) Distraction Osteogenesis, 3) Fibroblast heterogeneity and fibrosis repair, 4) Scarless Fetal Wound Healing, 5) Skeletal Stem Cells, 6) Novel Gene and Stem Cell Therapeutic Approaches.
-
Wan-Jin Lu
Basic Life Research Scientist, Stem Cell Bio Regenerative Med Institute
BioDr. Wan-Jin Lu is a Research Scientist in Dr. Phil Beachy's lab. Wan-Jin grew up in Taiwan, obtained her B.S. in Zoology at National Taiwan University and completed her PhD in Genetics and Development at UT Southwestern in the lab of Dr. John Abrams. Her Ph.D. research involved the identification of the evolutionary conserved function of the tumor suppressor gene p53 that ensures the quality control of germ cells. She then moved to the Bay Area, where she was a Damon Runyon Postdoctoral Fellow in the Institute of Stem Cell Biology and Regenerative Medicine in the Beachy lab. Her work currently focuses on understanding the function of Hedgehog signaling in taste receptor cell homeostasis and delineating the mechanisms of taste receptor regeneration after chemotherapy-induced loss.
Since 2017, she has been collaborating with Tabula Muris And Tabula Sapiens Consortium to investigate taste receptor stem cell renewal and regeneration in the Beachy lab. Her work has received funding support from California Institute of Regenerative Medicine (CIRM), Thomas and Stacey Siebel Foundation, and NIH (R21 and R01). -
Ravi Majeti MD, PhD
Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia and D. K. Ludwig Professor and Professor of Medicine (Hematology)
Current Research and Scholarly InterestsThe Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.
-
Masashi Miyauchi
Postdoctoral Scholar, Stem Cell Biology and Regenerative Medicine
BioMasashi Miyauchi, MD, PhD, is a physician-scientist specializing in hematology, oncology, immunology, and stem cell biology, with over a decade of experience in clinical hematology and oncology. Dr. Miyauchi's academic career commenced at Kyoto University, where he obtained his MD in Medicine. He furthered his expertise with a PhD in Internal Medicine from The University of Tokyo, Graduate School of Medicine. Following his comprehensive clinical training and professional appointments at The University of Tokyo Hospital, Dr. Miyauchi embarked on a postdoctoral journey at Stanford University in the Nakauchi lab, starting in July 2019.
Dr. Miyauchi's clinical training is extensive, including a Senior Residency in Internal Medicine and a Clinical Fellowship in Hematology and Oncology at The University of Tokyo Hospital. This period was complemented by his participation in a Cancer Professional Training Plan. After completing his clinical fellowship, Dr. Miyauchi has served in various pivotal roles at The University of Tokyo Hospital and The University of Tokyo. His positions as a clinically-focused Project Assistant Professor and Assistant Professor in the Department of Hematology and Oncology have enabled him to contribute significantly to pioneering research and education for the next wave of medical professionals.
In his PhD research, Dr. Miyauchi specialized in the disease modeling of cancers and cancer stem cells, employing cancer patient-specific induced pluripotent stem cells (iPSCs). His work with iPSCs notably includes scalable ex vivo manufacturing of human neutrophils. In his postdoctoral research under the guidance of Dr. Hiromitsu Nakauchi in Genetics at Stanford, Dr. Miyauchi has been concentrating on developing a stable hematopoietic stem cell (HSC) expansion system in both mouse and human models. His research is focused on exploring the potential applications of this expansion system, underlining his commitment to advancing the fields of stem cell biology, regenerative medicine and oncology. -
Michelle Monje
Milan Gambhir Professor of Pediatric Neuro-Oncology and Professor, by courtesy, of Neurosurgery, of Pediatrics, of Pathology and of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsThe Monje Lab studies the molecular and cellular mechanisms of postnatal neurodevelopment. This includes microenvironmental influences on neural precursor cell fate choice in normal neurodevelopment and in disease states.
-
Hiromitsu (Hiro) Nakauchi
Professor of Genetics (Stem Cell)
Current Research and Scholarly InterestsTranslation of discoveries in basic research into practical medical applications
-
Yusuke Nakauchi
Instructor, Institute for Stem Cell Biology and Regenerative Medicine
Current Research and Scholarly InterestsFrom 2005 to 2010, my work as a clinical hematology fellow allowed me to experience first-hand how scientific advances that started in a laboratory can transform patients' lives. While many of my patients were cured of their disease with allogeneic hematopoietic stem cell transplantation, underscoring the importance of anti-tumor immunotherapy in eradicating leukemia, I witnessed face-to-face their suffering from the long-term consequence of graft-versus-host disease (GVHD). This experience was ultimately what drove me to engage in research to discover novel therapies. For this reason, I embarked on a Ph.D. program in 2010 to design antibody therapy to (i) target GVHD and (ii) target hematological malignancies. Under the mentorship of Professor Hiromitsu Nakauchi at the University of Tokyo, an international leader in hematopoiesis, I developed allele-specific anti-human leukocyte antigen (HLA) monoclonal antibodies for severe GVHD caused by HLA-mismatched hematopoietic stem cell transplantation (Nakauchi et al., Exp Hematol, 2015). This study was the first to find that anti-HLA antibodies can be used therapeutically against GVHD. That success gave me the motivation and confidence to further my research beyond targeting GVHD to targeting leukemic stem cells through my postdoctoral fellowship in the laboratory of Professor Ravindra Majeti here at Stanford University.
Many people suffer from leukemia each year, but we still don't know how to cure it completely. Recent advances in sequencing technologies have tremendously improved our understanding of the underlying mutations that drive hematologic malignancies. However, the reality is that most of the mutations are not easily "druggable," and the discovery of these mutations has not yet significantly impacted patient outcomes. This is perhaps the most crucial challenge facing a translational cancer researcher like myself. My current research is a major step toward my long-term goal of making personalized medicine a reality for patients with acute myeloid leukemia (AML) and other hematologic malignancies.
Since joining the Majeti lab, I have been targeting the ten-eleven translocation methylcytosine dioxygenase-2 (TET2) mutation, which is aberrant in leukemia at a high rate and has been studied using human-derived cells. TET2 is known to be involved in the clonal expansion of cells, and people with this mutation are more likely to suffer from hematologic malignancies. It is also known to be involved in the development of coronary artery disease, a gene that has attracted much attention in recent studies. In my field, it is an essential gene involved in the abnormal proliferation of hematopoietic stem cells. Focusing on this gene, I mapped TET2-dependent 5hmC, epigenetic and transcriptional programs matched to competitive advantage, myeloid skewing, and reduced erythroid output in TET2-deficient hematopoietic stem and progenitor cells (HSPC). Vitamin C and azacitidine restore the 5hmC landscape and phenotypes in TET2-mutant HSPCs. These findings offer a comprehensive resource for TET-dependent transcriptional regulation of human hematopoiesis and shed light on the potential mechanisms by which TET deficiency contributes to clonal hematopoiesis and malignancies. Of course, these findings would also be of value in understanding the biology of normal hematopoietic stem cells (HSCs) and various other TET2-related cancers.
And from now on, I would like to use the single-cell transplantation techniques mastered in the Majeti lab to study the behavior of normal and aberrant human HSCs using various new methods, ultimately preventing the progression of AML.
In my clinical experience, I have lost many AML patients. With the regret and sadness of losing these patients in my heart, I hope to one day contribute to developing treatments that will fundamentally change how the world treats leukemia. -
Gernot Neumayer
Sr Res Scientist-Basic Life, Stem Cell Bio Regenerative Med Institute
BioI am a passionate scientist with expertise in basic and translational research related to ageing, cancer, genomic instability, DNA damage response (HDR & NHEJ), genome editing (CRISPR), regenerative medicine (iPSCs), cellular identity (reprogramming), and proteomics (interactions, biomarkers, target identification). My extensive experience is reflected by 10 peer reviewed publications. I possess excellent communication and technical writing skills (English/German), as evidenced by collaborations with world renowned institutions and >$460,000 won from scholarships, grants & awards. Recent highlights: Postdoctoral Young Investigator Award from Stanford University for scientific merit, commitment & leadership; “Played a big part” in securing a CRISPR-based $5.1Mio grant for regenerative medicine at Stanford University; Poster prize (out of 77 entries) at the Department of Pathology, Stanford University 2019 research day.
-
Aaron Newman
Assistant Professor of Biomedical Data Science
Current Research and Scholarly InterestsOur group develops computational strategies to study the phenotypic diversity, differentiation hierarchies, and clinical significance of tumor cell subsets and their surrounding microenvironments. Key results are further explored experimentally, both in our lab and through collaboration, with the ultimate goal of translating promising findings into the clinic.
-
Roeland Nusse
Virginia and Daniel K. Ludwig Professor of Cancer Research
Current Research and Scholarly InterestsOur laboratory studies Wnt signaling in development and disease. We found recently that Wnt proteins are unusual growth factors, because they are lipid-modified. We discovered that Wnt proteins promote the proliferation of stem cells of various origins. Current work is directed at understanding the function of the lipid on the Wnt, using Wnt proteins as factors the expand stem cells and on understanding Wnt signaling during repair and regeneration after tissue injury.
-
Lucy Erin O'Brien
Associate Professor of Molecular and Cellular Physiology
Current Research and Scholarly InterestsMany adult organs tune their functional capacity to variable levels of physiologic demand. Adaptive organ resizing breaks the allometry of the body plan that was established during development, suggesting that it occurs through different mechanisms. Emerging evidence points to stem cells as key players in these mechanisms. We use the Drosophila midgut, a stem-cell based organ analogous to the vertebrate small intestine, as a simple model to uncover the rules that govern adaptive remodeling.
-
Anthony Oro, MD, PhD
Eugene and Gloria Bauer Professor
Current Research and Scholarly InterestsOur lab uses the skin to answer questions about epithelial stem cell biology, differentiation and carcinogenesis using genomics, genetics, and cell biological techniques. We have studied how hedgehog signaling regulates regeneration and skin cancer, and how tumors evolve to develop resistance. We study the mechanisms of early human skin development using human embryonic stem cells. These fundamentals studies provide a greater understanding of epithelial biology and novel disease therapeutics.
-
Theo Palmer
Professor of Neurosurgery, Emeritus
Current Research and Scholarly InterestsMembers of the Palmer Lab study the biology of neural stem cells in brain development and in the adult. Our primary goal is to understand how genes and environment synergize in influencing stem cell behavior during development and how mild genetic or environmental risk factors for disease may synergize in their detrimental effects on brain development or in the risk of neuronal loss in age-related degenerative disease.
-
Matthew Porteus
Sutardja Chuk Professor of Definitive and Curative Medicine
BioDr. Porteus was raised in California and was a local graduate of Gunn High School before completing A.B. degree in “History and Science” at Harvard University where he graduated Magna Cum Laude and wrote an thesis entitled “Safe or Dangerous Chimeras: The recombinant DNA controversy as a conflict between differing socially constructed interpretations of recombinant DNA technology.” He then returned to the area and completed his combined MD, PhD at Stanford Medical School with his PhD focused on understanding the molecular basis of mammalian forebrain development with his PhD thesis entitled “Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development.” After completion of his dual degree program, he was an intern and resident in Pediatrics at Boston Children’s Hospital and then completed his Pediatric Hematology/Oncology fellowship in the combined Boston Chidlren’s Hospital/Dana Farber Cancer Institute program. For his fellowship and post-doctoral research he worked with Dr. David Baltimore at MIT and CalTech where he began his studies in developing homologous recombination as a strategy to correct disease causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, he took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before again returning to Stanford in 2010 as an Associate Professor. During this time his work has been the first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients and is considered one of the pioneers and founders of the field of genome editing—a field that now encompasses thousands of labs and several new companies throughout the world. His research program continues to focus on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle. Clinically, Dr. Porteus attends at the Lucille Packard Children’s Hospital where he takes care of pediatric patients undergoing hematopoietic stem cell transplantation.
